Topic summary

Second pass at: Semaglutide and alcohol: what is actually documented

Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 20, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

OkaforTL3Regular16 May 2025#3

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

25 likes 14mo

f.ibarraTL2 Moderator19 May 2025#4

Okafor, post #3: On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome. Go to post

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

12 likes in reply to #3 14mo

c.marchettiTL2 Moderator31 May 2025#8

ma.balogun, post #6: post #5 is right about the mechanism and I think understates the practical bit. Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather… Go to post

Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.

17 likes in reply to #6 14mo

i.brobergTL2 Moderator13 Jun 2025 · edited#13

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

12 likes 13mo

b.brandtTL2 Moderator22 Jun 2025#17

Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.

18 likes 13mo

Read the full topic (20 posts)

This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…	+61	65	1.3k	22mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Compounds › Semaglutide SELECT trial type 2 diabetes semaglutide Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+112	119	3.3k	11mo
Molecular mass of semaglutide and why the figure differs between sources Compounds › Semaglutide SELECT trial effect size semaglutide STEP programme Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+101	110	12k	16h
Tracking semaglutide's approved indications across jurisdictions, dated Compounds › Semaglutide semaglutide effect size SELECT trial Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+15	19	2.8k	1d

Related topics — sharing the tags semaglutide, type 2 diabetes, effect size

Topic	Participants	Replies	Views	Activity
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…	+109	124	31k	10mo
Criticising the method without criticising the authors — one year on Evidence › Study critique confounding effect size disputed risk of bias Solved Closed On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…	+16	20	61k	11mo
Journal club: STEP 4 and what a withdrawal design can prove — one year on Evidence › Journal club number needed to treat estimand randomised trial effect size Closed Journal club: STEP 4 and what a withdrawal design can prove — one year on Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024).…	+56	62	34k	15mo
About the Statistics category Research Methods › Statistics effect size number needed to treat heterogeneity Pinned Wiki Effect sizes, intervals, multiplicity, and the difference between absent and undetected. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…	+4	8	2.3k	7mo